Compare Stocks → Your Money is Not Safe (From American Alternative) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTONASDAQ:ATRANASDAQ:GNFTNASDAQ:MGTXNASDAQ:REPL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$1.16-4.9%$1.56$1.15▼$8.70$18.24M1.2987,161 shs47,086 shsATRAAtara Biotherapeutics$0.70-1.4%$0.72$0.20▼$3.02$83.53M0.692.67 million shs865,826 shsGNFTGenfit$3.45-1.1%$3.58$2.89▼$4.75$171.93M1.0814,880 shs12,609 shsMGTXMeiraGTx$4.71-3.1%$5.85$3.49▼$8.35$302.46M1.29154,257 shs121,649 shsREPLReplimune Group$6.15-2.8%$7.86$5.86▼$24.81$377.54M1.211.33 million shs783,453 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences-4.92%-8.66%-27.50%-41.41%-83.67%ATRAAtara Biotherapeutics-2.08%+1.17%+5.87%+16.19%-74.37%GNFTGenfit+0.15%0.00%-1.99%-9.92%-6.76%MGTXMeiraGTx-3.09%-5.99%-23.54%-30.22%-12.45%REPLReplimune Group-2.84%-11.76%-20.03%-20.95%-63.17%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTOAptose Biosciences2.6712 of 5 stars3.55.00.00.02.80.00.6ATRAAtara Biotherapeutics3.7498 of 5 stars3.01.00.04.72.62.50.6GNFTGenfit0.7041 of 5 stars3.52.00.00.00.60.00.0MGTXMeiraGTx4.1544 of 5 stars3.53.00.04.81.91.70.6REPLReplimune Group4.5009 of 5 stars3.51.00.04.53.73.31.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences3.00Buy$19.801,606.90% UpsideATRAAtara Biotherapeutics2.00Hold$28.003,901.14% UpsideGNFTGenfit3.00Buy$11.00218.84% UpsideMGTXMeiraGTx3.00Buy$25.67444.94% UpsideREPLReplimune Group3.00Buy$37.67512.47% UpsideCurrent Analyst RatingsLatest ATRA, REPL, APTO, GNFT, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.004/3/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$5.003/27/2024APTOAptose BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.002/1/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $5.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AATRAAtara Biotherapeutics$8.57M9.75N/AN/A($0.97) per share-0.72GNFTGenfit$28.57M6.02N/AN/A$1.48 per share2.33MGTXMeiraGTx$14.02M21.58N/AN/A$2.17 per share2.17REPLReplimune GroupN/AN/AN/AN/A$9.80 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$7.72N/AN/AN/AN/A-458.70%-205.30%5/13/2024 (Estimated)ATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.23N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)REPLReplimune Group-$174.28M-$3.16N/AN/AN/AN/A-42.94%-35.80%5/16/2024 (Estimated)Latest ATRA, REPL, APTO, GNFT, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ATRAAtara Biotherapeutics-$0.61-$0.56+$0.05-$0.56$2.45 million$4.25 million3/26/2024Q4 2023APTOAptose Biosciences-$1.48-$1.44+$0.04-$1.44N/AN/A3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million2/8/2024Q3 2024REPLReplimune Group-$0.89-$0.77+$0.12-$0.77N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A0.780.78ATRAAtara BiotherapeuticsN/A0.720.65GNFTGenfit0.922.942.94MGTXMeiraGTx0.622.382.38REPLReplimune Group0.1612.4012.40OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%ATRAAtara Biotherapeutics70.90%GNFTGenfit2.24%MGTXMeiraGTx67.48%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences9.53%ATRAAtara Biotherapeutics4.50%GNFTGenfit4.20%MGTXMeiraGTx9.70%REPLReplimune Group20.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences3115.72 million14.22 millionNo DataATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableGNFTGenfit15949.84 million47.74 millionNot OptionableMGTXMeiraGTx41964.22 million57.99 millionOptionableREPLReplimune Group28461.39 million48.74 millionOptionableATRA, REPL, APTO, GNFT, and MGTX HeadlinesSourceHeadlineVontobel Holding Ltd. Takes $2.58 Million Position in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - April 19 at 5:37 AMVanguard Group Inc. Increases Stake in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - April 10 at 4:00 AMInterim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meetingglobenewswire.com - April 7 at 5:00 PMReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 4 at 8:00 AMFive things: Downtown building sale, nursing home lawsuit, Fast 50 and the clock is tickingbizjournals.com - March 30 at 9:59 AMReplimune appoints new CEO ahead of drug applicationuk.investing.com - March 29 at 12:50 AMPetri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron dealbizjournals.com - March 28 at 9:48 AMReplimune Names Sushil Patel as CEO in Broader Shakeupmarketwatch.com - March 26 at 12:12 PMReplimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEOmarkets.businessinsider.com - March 26 at 12:12 PMReplimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitionsglobenewswire.com - March 26 at 7:30 AMREPL Apr 2024 10.000 callfinance.yahoo.com - March 16 at 12:31 PMREPL Mar 2024 10.000 putfinance.yahoo.com - March 15 at 4:28 PMHow Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%zacks.com - March 11 at 10:56 AMWhat Makes Replimune Group, Inc. (REPL) a New Buy Stockzacks.com - March 8 at 1:01 PMReplimune to Present at the American Association for Cancer Research Annual Meeting 2024finance.yahoo.com - March 6 at 7:31 PMReplimune to Present at Three Upcoming Investor Conferencesfinance.yahoo.com - March 5 at 10:04 AMWall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?zacks.com - February 23 at 10:56 AMPositive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trialsmarkets.businessinsider.com - February 15 at 6:48 PMAnalysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)markets.businessinsider.com - February 9 at 7:41 AMReplimune Group Is Worried About This – Should You Be Worried Too?msn.com - February 9 at 7:41 AMReplimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Updatefinance.yahoo.com - February 8 at 11:10 AMReplimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runwayfinance.yahoo.com - February 8 at 11:10 AMReplimune Group Inc (REPL)investing.com - February 8 at 12:00 AMDisc Medicine Taps Ex-Replimune Exec for CFO, Promotes New Operations Chiefmarketwatch.com - February 7 at 8:58 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Asian benchmarks mostly climb despite worries about US economyApril 26, 2024 3:21 AMView Stock market today: Asian benchmarks mostly climb despite worries about US economyFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come3 High Dividend Stocks to Replace Lower Savings Yields AheadApril 9, 2024 9:15 AMView 3 High Dividend Stocks to Replace Lower Savings Yields AheadAll Headlines Company DescriptionsAptose BiosciencesNASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Atara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.GenfitNASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Replimune GroupNASDAQ:REPLReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.